Advertisement
Research Article

Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient

  • Ninette Amariglio,

    Affiliations: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Abraham Hirshberg,

    Affiliation: Department of Oral Pathology, School of Dental Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Bernd W Scheithauer,

    Affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America

    X
  • Yoram Cohen,

    Affiliation: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Ron Loewenthal,

    Affiliation: Tissue Typing Laboratory, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Luba Trakhtenbrot,

    Affiliation: Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Nurit Paz,

    Affiliation: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Maya Koren-Michowitz,

    Affiliation: Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Dalia Waldman,

    Affiliation: Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Leonor Leider-Trejo,

    Affiliation: Institute of Pathology, Tel-Aviv Medical Center, Tel-Aviv, Israel

    X
  • Amos Toren,

    Affiliation: Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Shlomi Constantini,

    Affiliation: Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Gideon Rechavi mail

    To whom correspondence should be addressed. E-mail: gidi.rechavi@sheba.health.gov.il

    Affiliations: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Published: February 17, 2009
  • DOI: 10.1371/journal.pmed.1000029

Reader Comments (11)

Post a new comment on this article

Response to "Immune sensitization might kill tumors"

Posted by plosmedicine on 31 Mar 2009 at 00:35 GMT

Author: Gideon Rechavi
Position: Professor
Institution: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine
E-mail: gidi.rechavi@sheba.health.gov.il
Additional Authors: Ninette Amariglio
Submitted Date: March 09, 2009
Published Date: March 9, 2009
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

We are of course aware of your pioneering contribution to the field of transplantation for Parkinson's disease.

Your idea regarding immunization as a potential treatment for such mishaps is very interesting. In the case we described there is no way to get "donor" cells but the possibility you raise regarding tissues from other donors is a possibility with all the potential risks you mentioned.

We thought that if there will be a need for an additional therapy maybe a kind of stimulation of his own immune system can be attempted for example interferon or IL2. This is in line with your opinion that the child's immune system is the best hope for eliminating the cell masses.

No competing interests declared.